Browsing by Author "Batmaz, Ibrahim"

Now showing 1 - 4 of 4

Comparison of Orexigenic and Anorexigenic Neuropeptide Levels in Hyperemesis Gravidarum Patients With Normal Pregnant Women: a Prospective Cohort Study
(Lippincott Williams & Wilkins, 2024) Balsak, Deniz; Aksin, Şerif; Balsak, Deniz; Aboalhasan, Yasmin; Batmaz, Ibrahim
Background: The aim of this study was to determine whether orexigenic neuropeptides, orexin and galanin, and anorexigenic neuropeptides, alpha-melanocyte-stimulating hormone (alpha-MSH) and cocaine- and amphetamine-regulated transcript (CART), are implicated in hyperemesis gravidarum (HG). Methods: Fifty pregnant women who had been diagnosed with HG between April 2022 and February 2023 at the Siirt University Faculty of Medicine Training and Research Hospital (tertiary center) were recruited for this study. An equal number of pregnant women without an HG diagnosis were included in the study as the control group. Participants' age, pregnancy history, medical history, thyroid function test results, complete blood count results, and electrolyte levels were recorded, and their orexin, galanin, alpha-MSH, and CART serum levels were analyzed using an enzyme-linked immunosorbent assay. Results: No statistically significant differences in orexigenic neuropeptides (orexin and galanin) were observed between the HG and control groups. A statistical difference was found between an anorexigenic neuropeptide (alpha-MSH) and the control group (P = .012). Based on a receiver operating characteristic analysis, the alpha-MSH parameter was statistically significant for distinguishing between participants with an HG diagnosis and those without, with a sensitivity of 63.6%, specificity of 65.9%, and cutoff value of 11769.3 pg/mL (P = .012, area under curve: 0.655). Based on the severity classification of ketonuria (ketonuria levels of +1 or +2 were classified as mild, whereas levels of +3 or +4 were classified as moderate to severe), the anorexigenic CART neuropeptide was found to be a statistically significant diagnostic indicator of severe ketonuria (P = .020). Conclusion: alpha-MSH and CART levels were found to be related in HG patients and in HG patients with severe ketonuria.
Evaluation of Visceral Adipokines: Omentin, Vaspin, and Visfatin in Patients With Gestational Diabetes Mellitus
(Imr Press, 2024) Balsak, Deniz; Aksin, Şerif; Bozbay, Nizamettin; Balsak, Deniz; Aboalhasan, Yasmin; Kurnuc, Fatma Zehra; Batmaz, Ibrahim
Background: Gestational diabetes mellitus (GDM) is a common metabolic disorder characterized by glucose intolerance that develops during pregnancy. The underlying pathophysiological mechanisms of GDM involve complex interactions between genetic, environmental, and hormonal factors, including adipokines secreted by visceral adipose tissue. Omentin, vaspin, and visfatin are adipokines believed to influence insulin sensitivity and inflammation, though their precise relationship with GDM remains unclear. This study aimed to examine the association between these adipokines and GDM. Methods: This single-center, prospective controlled cohort study included 87 pregnant patients diagnosed with GDM via an oral glucose tolerance test (OGTT) between the 24th and 28th weeks of gestation, along with 87 control subjects without GDM. Serum levels of omentin, vaspin, and visfatin were measured using enzyme-linked immunosorbent assay (ELISA), and their association with GDM was analyzed. Results: Our results demonstrated that omentin levels were significantly higher in the GDM group compared to the control group (p = 0.012), while no significant differences were observed in vaspin and visfatin levels (p > 0.05). An omentin cut-off value of 29.0 ng/mL predicted GDM with 59.1% sensitivity and 59.1% specificity, suggesting its potential as a biomarker for GDM. Conclusions: This study underscores the unique role of omentin in GDM, in contrast to the non-significant changes observed in vaspin and visfatin levels. The elevated omentin levels in GDM patients suggest its potential as a biomarker for diagnosing and managing GDM. Further research is needed to elucidate the mechanisms through which omentin contributes to the pathophysiology of GDM.
Relationship Between First Trimester Placental Thickness and Perinatal Prognosis: a Prospective Cohort Study
(Bayrakol Medical Publisher, 2025) Yilmaz, Mehmet; Aksin, Serif; Balsak, Deniz; Aboalhasan, Yasmin; Kurnuc, Fatma Zehra; Batmaz, Ibrahim
Aim: This study aims to investigate the correlation between first-trimester placental thickness and perinatal prognosis. Material and Methods: A prospective cohort study was conducted at Siirt University Faculty of Medicine from March 2022 to March 2023 of 365 pregnant women in their first trimester (11-14 weeks of gestation). Placental volume was measured using two-dimensional (2D) ultrasound, and estimated placental volume (EPV) was calculated using Merwin's EPV Calculator app. The patients were followed until delivery, and outcomes such as gestational age at delivery, mode of delivery, fetal weight, APGAR score, fetal gender, perinatal outcomes, preeclampsia (PE), premature rupture of membranes (PROM), gestational hypertension (GHT), gestational diabetes mellitus (GDM), intrauterine growth restriction (IUGR), preterm birth, oligohydramnios, polyhydramnios, surmaturation, presentation anomaly, intrauterine death, fetal distress, and placental abruption were evaluated. Results: Data from 365 pregnant women were analyzed. The mean maternal age was 27.2 +/- 5.5 years. The distribution of placental location was 38.4% posterior, 43.0% anterior, 7.4% left sidewall and 11.2% right sidewall. No significant differences were found in placental volume measurements based on delivery mode, fetal gender, or conditions such as PE, GDM, IUGR, PROM, preterm birth, or other perinatal pathologies. Statistical analyses showed no significant association between first-trimester placental volume and adverse perinatal outcomes (p>0.05). Discussion: No relationship was found between first-trimester placental thickness and perinatal outcomes.
The Role of Mid-Trimester Bun and Creatinine Assessment in Predicting Preeclampsia: Retrospective Case-Control Study
(Mdpi, 2025) Kavak, Ebru Celik; Akcabay, Cigdem; Demircan, Meryem; Batmaz, Ibrahim; Sanli, Cengiz; Senocak, Ahmet; Kavak, Salih Burcin
Background and Objectives: Preeclampsia (PE) is a major cause of adverse perinatal outcomes. Early diagnosis of pregnant women at risk of PE can facilitate disease prevention and management. However, the presence of different phenotypes of the disease complicates its prediction. In particular, the challenges in the early diagnosis of term PE cases necessitate research on PE prediction in the second and third trimesters. This study aims to examine the association between PE development and mid-trimester blood urea nitrogen (BUN), serum creatinine, and the BUN/creatinine ratio in pregnant women. Materials and Methods: This retrospective case-control study was conducted on women diagnosed with PE. Pregnant women who underwent routine biochemical blood tests between the 18th and 24th weeks of gestation and subsequently gave birth at our hospital between January 2022 and May 2023 were categorized into three groups. Accordingly, healthy women who had term deliveries were classified as Group 1 (150 cases), women diagnosed with PE were classified as Group 2 (58 cases), and those diagnosed with severe PE were classified as Group 3 (44 cases). Results: There were no significant differences in age, gravidity, parity, body mass index, or gestational week at blood sampling between the patient and control groups (p > 0.05). When comparing the mean blood urea nitrogen, serum creatinine, and BUN/creatinine ratios, a significant difference was observed between the control group and those who developed PE (p = 0.001, p < 0.001, and p = 0.031, respectively). Univariate analysis revealed a significant association between BUN levels and PE development (OR 1.083; 95% CI, 1.031-1.139; p = 0.002). A stronger association was observed between serum creatinine levels and PE development (OR 112.344; 95% CI, 11.649-1083.416; p < 0.001). However, no significant association was found between the BUN/creatinine ratio and PE in univariate analysis (OR 1.003; 95% CI, 0.979-1.028; p > 0.05). Mid-trimester BUN and serum creatinine levels were significantly higher in patients who developed PE and severe PE. The AUC value for the BUN parameter in predicting PE was 0.614 (AUC 0.614; 95% CI, 0.539-0.689; p = 0.002). A BUN cut-off value of 16.2 mg/dL predicted disease development with a sensitivity of 52.9% and a specificity of 74%. Similarly, the AUC value for the serum creatinine parameter in predicting PE was 0.644 (AUC 0.644; 95% CI, 0.574-0.751; p < 0.001). A serum creatinine cut-off value of 0.58 mg/dL was able to predict disease development with 37.2% sensitivity and 88% specificity. No significant AUC value was obtained for the BUN/creatinine ratio (p > 0.05). Conclusions: Our findings indicate that elevated BUN and serum creatinine levels measured during the mid-trimester (18-24 weeks) are associated with an increased risk of developing preeclampsia.